Oncolytics Biotech Inc.’s Q4 2024 Results Conference Call: Key Insights
On March 7, 2025, Oncolytics Biotech Inc. (NASDAQ: ONCY) held its Fourth Quarter and Full Year 2024 conference call. The call was hosted by Jon Patton, Director of Investor Relations and Communications, with participation from Wayne Pisano, Chairman of Oncotic’s Board of Directors and Interim CEO, Tom Heineman, Chief Medical Officer, Kirk Look, Chief Financial Officer, and Christophe Degois, Vice President of Business Development. Michael Freeman from Raymond James and Luis Santos from H.C. Wainwright were among the participants.
Company Highlights
During the call, the company provided updates on its clinical programs and business development activities. They announced that their lead product, REOLYSIN, met its primary endpoint in the Phase 3 REO 024 study in metastatic colorectal cancer. The study achieved a statistically significant improvement in progression-free survival compared to the control arm. The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2025.
Clinical Programs
Oncolytics also provided updates on their other clinical programs. The Phase 3 REO 031 study in head and neck cancer is ongoing, and the company expects to report top-line data in the second half of 2025. They also announced the initiation of the Phase 1b/2 study of REOLYSIN in combination with Merck’s KEYTRUDA (pembrolizumab) in advanced solid tumors. The study will evaluate the safety, tolerability, and efficacy of the combination.
Business Development
In terms of business development, Oncolytics announced a collaboration with Merck KGaA to develop and commercialize REOLYSIN in Europe and other parts of the world, excluding the United States and Japan. The collaboration includes an upfront payment of $10 million and potential milestone payments up to $315 million.
Impact on Individuals
For individuals living with metastatic colorectal cancer, the potential approval of REOLYSIN could mean a new treatment option with the potential to improve progression-free survival. However, it is important to note that this is still a developing treatment and further clinical trials and regulatory approvals are needed before it can be widely available to patients.
Impact on the World
If approved, REOLYSIN could represent a significant advancement in the treatment of metastatic colorectal cancer. According to the American Cancer Society, an estimated 149,500 new cases of colorectal cancer will be diagnosed in the United States in 2025, and approximately 53,200 people will die from the disease. A new, effective treatment option could help improve outcomes for many of these individuals and reduce the overall burden of colorectal cancer on society.
Conclusion
Oncolytics Biotech’s Q4 2024 conference call provided several key updates on their clinical programs and business development activities. The announcement of positive results from the Phase 3 REO 024 study in metastatic colorectal cancer and the collaboration with Merck KGaA to develop and commercialize REOLYSIN in Europe and other parts of the world are significant developments for the company. For individuals living with metastatic colorectal cancer, the potential approval of REOLYSIN could represent a new treatment option with the potential to improve progression-free survival. For the world, a new, effective treatment option could help reduce the overall burden of colorectal cancer on society.
- Oncolytics Biotech announces positive results from Phase 3 REO 024 study in metastatic colorectal cancer
- Collaboration with Merck KGaA to develop and commercialize REOLYSIN in Europe and other parts of the world
- Potential approval of REOLYSIN could represent a new treatment option for metastatic colorectal cancer
- Further clinical trials and regulatory approvals needed before REOLYSIN can be widely available to patients
- REOLYSIN could help improve outcomes for many individuals with metastatic colorectal cancer and reduce the overall burden of the disease on society
